From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...
A new treatment for Hodgkin lymphoma has been recommended for routine use on the NHS. Around 800 people with the advanced form of blood cancer could benefit, it is believed. The condition develops ...
Cancer Center have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response ...
A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
News Medical on MSN1d
Novel NK cell therapy shows strong response in lymphoma patientsA novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...
Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...
Coulier announced his cancer diagnosis during a November 2024 appearance on the Today show, revealing he had a “very aggressive” form of stage 3 non-Hodgkin’s lymphoma. Non-Hodgkins lymphoma ...
Lymphoma is a type of cancer that begins in immune system cells, called lymphocytes. It generally presents as a solid tumor of lymphoid cells and can develop in the lymph nodes, spleen, bone ...
New combination therapy will be available on the NHS, offering new hope to people with advanced Hodgkin lymphoma ...
We thank Yutaka Shimazu for his constructive comments on our HD21 trial.1 In the PET-2 positive cohort, 165 (69%) of 240 patients treated with brentuximab vedotin, etoposide, cyclophosphamide, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback